Meeting
2014 Gastrointestinal Cancers Symposium
A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.
Authors
Yousuke Nakai
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Yousuke Nakai , Hiroyuki Isayama , Takashi Sasaki , Kei Saito , Naminatsu Takahara , Suguru Mizuno , Tsuyoshi Hamada , Koji Miyabayashi , Keisuke Yamamoto , Hirofumi Kogure , Natsuyo Yamamoto , Kenji Hirano , Hideaki Ijichi , Keisuke Tateishi , Minoru Tada , Kazuhiko Koike
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000007556
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 290)
DOI
10.1200/jco.2014.32.3_suppl.290
Abstract #
290
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
First Author: Masafumi Ikeda
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03).
First Author: Vaibhav Sahai
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich